Literature DB >> 23669225

Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: time to think differently?

Michael L Friedlander, Martin Richard Stockler, Phyllis Butow, Madeleine Trudy King, Jessica McAlpine, Anna Tinker, Jonathan A Ledermann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23669225     DOI： 10.1200/JCO.2012.47.7927

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  11 in total

1.  Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.

Authors:  Boris Winterhoff; Stefan Kommoss; Florian Heitz; Gottfried E Konecny; Sean C Dowdy; Sally A Mullany; Tjoung-Won Park-Simon; Klaus Baumann; Felix Hilpert; Sara Brucker; Andreas du Bois; Willibald Schröder; Alexander Burges; Steven Shen; Jinhua Wang; Roshan Tourani; Sisi Ma; Jacobus Pfisterer; Constantin F Aliferis
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

2.  Association analysis of a chemo-response signature identified within The Cancer Genome Atlas aimed at predicting genetic risk for chemo-response in ovarian cancer.

Authors:  Erin A Salinas; Andreea M Newtson; Kimberly K Leslie; Jesus Gonzalez-Bosquet
Journal:  Int J Mol Epidemiol Genet       Date:  2016-03-23

Review 3.  Management of recurrent epithelial ovarian cancer.

Authors:  Víctor Manuel Vargas-Hernández; Mario Adan Moreno-Eutimio; Gustavo Acosta-Altamirano; Víctor Manuel Vargas-Aguilar
Journal:  Gland Surg       Date:  2014-08

4.  Whole-genome characterization of chemoresistant ovarian cancer.

Authors:  Ann-Marie Patch; Elizabeth L Christie; Dariush Etemadmoghadam; Dale W Garsed; Joshy George; Sian Fereday; Katia Nones; Prue Cowin; Kathryn Alsop; Peter J Bailey; Karin S Kassahn; Felicity Newell; Michael C J Quinn; Stephen Kazakoff; Kelly Quek; Charlotte Wilhelm-Benartzi; Ed Curry; Huei San Leong; Anne Hamilton; Linda Mileshkin; George Au-Yeung; Catherine Kennedy; Jillian Hung; Yoke-Eng Chiew; Paul Harnett; Michael Friedlander; Michael Quinn; Jan Pyman; Stephen Cordner; Patricia O'Brien; Jodie Leditschke; Greg Young; Kate Strachan; Paul Waring; Walid Azar; Chris Mitchell; Nadia Traficante; Joy Hendley; Heather Thorne; Mark Shackleton; David K Miller; Gisela Mir Arnau; Richard W Tothill; Timothy P Holloway; Timothy Semple; Ivon Harliwong; Craig Nourse; Ehsan Nourbakhsh; Suzanne Manning; Senel Idrisoglu; Timothy J C Bruxner; Angelika N Christ; Barsha Poudel; Oliver Holmes; Matthew Anderson; Conrad Leonard; Andrew Lonie; Nathan Hall; Scott Wood; Darrin F Taylor; Qinying Xu; J Lynn Fink; Nick Waddell; Ronny Drapkin; Euan Stronach; Hani Gabra; Robert Brown; Andrea Jewell; Shivashankar H Nagaraj; Emma Markham; Peter J Wilson; Jason Ellul; Orla McNally; Maria A Doyle; Ravikiran Vedururu; Collin Stewart; Ernst Lengyel; John V Pearson; Nicola Waddell; Anna deFazio; Sean M Grimmond; David D L Bowtell
Journal:  Nature       Date:  2015-05-28       Impact factor: 49.962

Review 5.  Ovarian cancer treatment: The end of empiricism?

Authors:  Stephanie Lheureux; Katherine Karakasis; Elise C Kohn; Amit M Oza
Journal:  Cancer       Date:  2015-06-10       Impact factor: 6.860

6.  Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.

Authors:  Rong Liu; Ying Zeng; Cheng-Fang Zhou; Ying Wang; Xi Li; Zhao-Qian Liu; Xiao-Ping Chen; Wei Zhang; Hong-Hao Zhou
Journal:  Sci Rep       Date:  2017-02-02       Impact factor: 4.379

7.  High Expression Levels of AGGF1 and MFAP4 Predict Primary Platinum-Based Chemoresistance and are Associated with Adverse Prognosis in Patients with Serous Ovarian Cancer.

Authors:  Haiyue Zhao; Qian Sun; Lisong Li; Jinhua Zhou; Cong Zhang; Ting Hu; Xuemei Zhou; Long Zhang; Baiyu Wang; Bo Li; Tao Zhu; Hong Li
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

8.  Gene Expression Indicates Altered Immune Modulation and Signaling Pathway Activation in Ovarian Cancer Patients Resistant to Topotecan.

Authors:  Otília Menyhárt; János Tibor Fekete; Balázs Győrffy
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

9.  Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival.

Authors:  Nicholas Cardillo; Douglas Russo; Andreea Newtson; Henry Reyes; Yasmin Lyons; Eric Devor; David Bender; Michael J Goodheart; Jesus Gonzalez-Bosquet
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

10.  Prediction of chemo-response in serous ovarian cancer.

Authors:  Jesus Gonzalez Bosquet; Andreea M Newtson; Rebecca K Chung; Kristina W Thiel; Timothy Ginader; Michael J Goodheart; Kimberly K Leslie; Brian J Smith
Journal:  Mol Cancer       Date:  2016-10-19       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.